APA (7th ed.) Citation

Deodhar, A., Nowak, M., Ye, J. Y., Lehman, T., Banerjee, S., & Mease, P. J. (2025). Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis. Rheumatology & Therapy, 12(5), 873. https://doi.org/10.1007/s40744-025-00776-4

Chicago Style (17th ed.) Citation

Deodhar, Atul, Miroslawa Nowak, June Y. Ye, Tom Lehman, Subhashis Banerjee, and Philip J. Mease. "Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis." Rheumatology & Therapy 12, no. 5 (2025): 873. https://doi.org/10.1007/s40744-025-00776-4.

MLA (9th ed.) Citation

Deodhar, Atul, et al. "Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis." Rheumatology & Therapy, vol. 12, no. 5, 2025, p. 873, https://doi.org/10.1007/s40744-025-00776-4.